

Simultaneous Platinol and 5-Fluorouracil With Field Within Field Boosting Technique in Management of Advanced Head and Neck Cancer

Thesis

Submitted for the partial fulfillment of the MD Degree in Radiation Oncology and Nuclear Medicine

By

Eman Mohamed Fouad El-Said MB, B Ch, M Sc

Supervised by

Prof. Dr. Laila Faris Matta

Head and Prof. of Radiation Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University

Prof. Dr. Mohamed El Kahky

Prof. of ENT Faculty of Medicine - Ain Shams University

Prof. Dr. Salwa Massoud Ibrahim

Prof. of Radiation Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University

Ass. Prof. Dr. Soheir Helmy Mahmoud

Assistant Prof. of Radiation Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
1997



بسمرالله الرحمن الرحيم

TO MY HUSBAND AND MY SON



Acknowledgement

I would like to express my profound gratitude and sincere appreciation to **Prof. Dr. Laila Faris**, Head of Radiation Oncology and Nuclear Medicine Dept., Faculty of Medicine, Ain Shams University from whom I learned a lot both practically and scientifically, for her great help, continuous support and warm advise, without her help, this work would not come into existence.

I would like to express my deep thanks and sincere gratitude to **Prof. Dr. Salwa Massoud Ibrahim**, Professor of Radiation Oncology and Nuclear Medicine, Ain Shams University, for her guidance, valuable support, precious instructions and encouragement throughout this work.

I owe special gratefulness and much regards to **Prof. Dr. Mohamed El Kahky**, Professor of ENT, Faculty of Medicine,
Ain Shams University, for his limitless help, valuable advise,
guidance and encouragement during the preparation of the
thesis.

I was fortunate to carry out this work under the guidance of **Dr. Soheir Helmy Mahmoud**, Assistant Professor of Radiation Oncology and Nuclear Medicine, Ain Shams University. It was through her enthusiastic cooperation, infailing help,

advice, support and encouragement that this work have been accomplished.

There are no words of thanks or gratitude sufficient for my husband, Dr. Mohamed Esawi, for the time, effort he spent in publishing this work, for his encouragement, patience and continuous support.

Lastly, by no means the least, I thank all professors in Radiation Therapy Department, all my colleagues for their sincere help and cooperation during the accomplishment of this work.

Eman Fouad

Contents

Introduction and Aim of the Work	1
Review of Literature	
Epidemiology of Head and Neck Squamous Cell Carcinoma	4
Incidence	4
Risk Factors	5
Pathology of Head and Neck Cancer	7
Biological Behavior of Head and Neck Cancer	10
Oncogenes Abnormalities	10
Tumor Suppressor Genes	11
Growth Factors and Tumor Secretory Products	13
Standard Treatment of Head and Neck Carcinoma	16
Surgery in the Treatment of Head and Neck Cancer	17
Radiation Therapy in Treatment of Head and Neck Cancer	23
Chemotherapy	26
Altered Fractionation Schedules in Treatment of Head and Neck	
Cancers	30
Radiobiological Background	30
Rationale and Clinical Experience of Altered Fractionation Schedules in	
Treatment of Head and Neck Cancer	44
Combined Modality Treatment of Head and Neck Cancer	_57
I. Biological Aspects in Chemotherapeutic Agents	57
II. Biological Basis for Interactions of Chemotherapeutic Agents and Radio	ation61
III. Clinical Experience of Chemoradiation Modalities for Treating Head an	ıd
Neck Cancer	86
Newer Approaches to Treatment of Head and Neck Cancer	109
Three Dimensional Conformal Radiotherapy	109
Intra-Operative Radiation Therapy (IORT)	111
Particle Beam Radiation Therapy	114
Stereotactic Radiosurgery	117
Gene Therapy for Head and Neck Cancer	118
Photodynamic Therapy	119
Chemoprevention of Head and Neck Malignancies	120

Ain Shams University

Patients and Methods	124
Results	138
Discussion	181
Summary	201
Annex	203
References	207
Arabic Summary	

Ain Shams University

List of Abbreviations

2D	Two Dimensional	
3D-CRT	Three Dimensional Conformal Radiation Therapy	
5-FU	5-Fluorouracil	
AF	Accelerated Fractionation	
AJCC	American Joint Committee on Cancer	
BEV	Beam's Eye View	
bid	Twice Daily	
BSO	Buthionine Sulfoximine	
BTV	Biologic Target Volume	
CF	Conventional Fractionation	
cGy	Centigray	
CHART	Continuous Hyperfractionated Accelerated	
	Radiotherapy	
CMT	Combined Modality Therapy	
Co [∞]	Cobalt 60	
CR	Complete Response	
СТ	Chemotherapy	
CT Images	Computerized Tomography Images	
DEF	Dose Effect Factor	
EORTC	European Organization for Research and Treatment of	
	Cancer	
F/W	Fractions per Week	
Gy	Gray	
h	hour	
HF	Hyperfractionation	
IORT	Intra-operative Radiation Therapy	
iv	Intravenous	
KPS	Karnofsky Performance Scale	
Linac	Linear Accelerator	
L-Q	Linear-Quadratic	

<u> </u>	1	
Mev	Megaelectron Volt	
MV	Megavolt	
NC	No Change	
NEMROCK	Kasr El Aini Center of Radiation Oncology and Nuclear	
	Medicine.	
NPC	Nasopharyngeal Carcinoma	
NTCP	Normal Tissue Complications Probabilities	
PD	Progressive Disease	
PLD	Potential Lethal Damage	
PLDR	Potential Lethal Damage Repair	
PR	Partial Response	
PS	Performance Status	
RT	Radiation Therapy	
RTOG	Radiation Therapy Oncology Group	
SCARF	Split Course Accelerated Fractionation Schedules	
SCCHN	Squamous Cell Carcinoma of Head and Neck	
SLDR	Sublethal Damage Repair	
SSD	Source Skin Distance	
TCP	Tumor Control Probabilities	
TGF	Therapeutic Gain Factor	
TGFα	Transforming Growth Factor Alpha	
TIL	Tumor Infiltrating Lymphocytes	
Tpot	Potential Doubling Time	
vs	versus	
WHO	World Health Organization	

List of Tables

No.	Description	Page
Table 1	Classification of neck dissection	21
Table 2	Active Chemotherapy Agents and Response Rates (Collins et al., 1995)	27
Table 3	Selected Randomized Trials of Chemotherapy in Recurrent or Metastatic Disease	28
Table 4	Possible Mechanisms of CT-RT Interactions	69
Table 5	Possible mechanism of enhancement of radiation effects of 15 commonly used chemotherapeutic drugs	69
Table 6	Acute normal tissue toxicity according to WHO criteria (Beretta, 1991)	136
Table 7	Late radiation morbidity scoring scheme (RTOG, EORTC)	137
Table 8	Distribution of the 40 patients according to their age grouping	139
Table 9	Distribution of the 40 Patients According to Site of Primary Lesion	144
Table 10	Distribution of the 40 Patients According to TNM <i>AJCC</i> , (1988), Staging System	148
Table 11	The factors related to the patient characteristics which could affect the overall response rate	150
Table 12	The relation of overall response rate to TNM AJCC staging system	152
Table 13	Overall response rate of the 40 treated patients according to primary site and histopathologic grade	155
Table 14	Analysis of patterns of treatment failure in the studied 40 patients	159
Table 15	Relation of grade 3 and 4 mucositis to the site of the primary lesion	174
Table 16	Acute toxicity in the 40 patients according to WHO criteria (Beretta, 1991)	176